Mohammed Shubair, MD
Pulmonary Disease · Anniston, ALNPI 1861449233
Payments from drug & device makers
Across 341 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$715
- Grifols USA, LLC$599
- Sanofi$275
- Takeda Pharmaceuticals U.S.A., Inc.$265
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,33397%
- Education$1733%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 102 | $1,702 |
| AstraZeneca | 51 | $1,163 |
| Boehringer Ingelheim | 47 | $715 |
| Grifols USA, LLC | 28 | $599 |
| Sanofi | 12 | $275 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $265 |
| Mylan Specialty L.p. | 12 | $240 |
| Insmed, Inc. | 6 | $193 |
| Regeneron Healthcare Solutions, Inc. | 8 | $183 |
| Mallinckrodt Hospital Products Inc. | 7 | $129 |
| Philips North America LLC | 6 | $110 |
| Jazz Pharmaceuticals Inc. | 6 | $102 |
| Baxter Healthcare | 4 | $98 |
| Mallinckrodt Enterprises LLC | 4 | $78 |
| Advanced Respiratory, Inc | 3 | $65 |
| Cook Medical LLC | 3 | $64 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Actelion Pharmaceuticals US, Inc. | 3 | $52 |
| Vifor Pharma, Inc. | 2 | $46 |
| Bayer | 2 | $44 |
| Viatris Specialty LLC | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Shire North American Group Inc | 2 | $34 |
| Inogen, Inc. | 2 | $27 |
| Eisai Inc. | 2 | $26 |
| AbbVie | 2 | $25 |
| Pfizer | 1 | $23 |
| Merck | 1 | $22 |
| Pulmonx Corporation | 1 | $21 |
| Amgen | 1 | $18 |
| United Therapeutics Corporation | 1 | $18 |
| Apria Healthcare LLC | 1 | $12 |
| Mayne Pharma Commercial LLC | 1 | $12 |
| Galt Pharmaceuticals, LLC | 1 | $9 |
| Harmony Biosciences LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,506 in reported general payments places this provider in the 60th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 19 | $240,443 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 239 | $205,385 |
| OfevNintedanib Esylate | 15 | $190,491 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 170 | $121,935 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $29,067 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $14,442 |
| AirsupraAlbuterol Sulfate/Budesonide | 26 | $12,614 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,921 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 218 | $7,753 |
| Roflumilast | 29 | $7,058 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,449 |
| Theophylline ErTheophylline Anhydrous | 129 | $4,254 |
| Ventolin HfaAlbuterol Sulfate | 41 | $4,014 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $2,858 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $52 | $240,44319 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $715 | $226,00679 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,702 | $215,646271 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $1,163 | $148,990241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Anniston
- Rohit PatelAnniston$41K
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
- A RidgewaySheffield$434K
- Darryle BullardCullman$380K
- Marvin SextonDothan$346K
- Veena AntonyBirmingham$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.